

# Cordis Showcases Comprehensive Interventional Cardiology Portfolio with Coronary Stents at TCT 2017

**Cordis is Now the Exclusive U.S. Distributor of Medinol Coronary Stents**

**DUBLIN, Ohio, October 30, 2017** — Cordis, a Cardinal Health company, today unveiled a comprehensive interventional cardiology portfolio, which now includes two innovative coronary stents -- the TRYTON Side Branch Stent and Medinol's NIRxcell™, a cobalt-chromium bare metal stent (BMS). Cordis' cardiology products will be on display (booth #4130) during the 29th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation, in Denver.

The recent Cardinal Health agreement with Medinol, a company based in Israel that is dedicated to the science of cardiovascular intervention, gives Cordis exclusive rights to sell Medinol's coronary stent portfolio in the U.S. Cordis is now selling Medinol's NIRxcell™ BMS and, upon Medinol receiving U.S. Food and Drug Administration approval, Cordis will also be the exclusive distributor of the EluNIR™ drug-eluting stent (DES). The EluNIR™ DES is currently an investigational device and not approved for commercial use in the U.S.

"The new Medinol agreement, along with the recent launch of the TRYTON Side Branch Stent and two Meril PTCA Balloon Dilatation Catheters, reestablishes Cordis in the U.S. market with a significant interventional cardiology portfolio," said Peter Van Haur, vice president of North America Sales and Marketing, Cordis. "By adding these new products to our portfolio, we can make the most significant contribution to the healthcare system and deliver innovative products and solutions that our customers and their patients are seeking."

Medinol has a long, established history in the coronary stent market and has been an innovator for more than 20 years. The unique design of the company's products, along with its rigorous standards of manufacturing and safety, make the company a leading developer in this space.

Medinol's **NIRxcell™ Bare-Metal Stent and EluNIR™ Drug-Eluting Stent** are supported by a large body of clinical data. The NIRxcell™ BMS has been tested on more than 1,000 patients and found highly effective in numerous clinical trials. The EluNIR™ DES has demonstrated excellent results in two randomized clinical trials including more than 2,200 patients treated in the United States, Canada, Europe and Israel. Data from BIONICS, a global pivotal study of 1,919 patients from 76 sites in 8 countries, was submitted to FDA to support U.S. regulatory approval of the EluNIR™ DES for the treatment of patients with narrowing or blockages to their coronary arteries. The EluNIR™ DES is currently an investigational device and not approved for commercial use in the U.S. Medinol recently received CE-mark and other regulatory clearances in Europe for the EluNIR™ stent.

The **Tryton Side Branch Stent**, the first dedicated bifurcation device to receive regulatory approval in the U.S., is approved for the treatment of de novo coronary bifurcation lesions involving large side branches (appropriate for a  $\geq 2.5$ mm stent). Cordis, Cardinal Health's interventional vascular business, is the exclusive U.S. distributor of the Tryton Side Branch Stent.

The Tryton Side Branch Stent System is built using proprietary Tri-ZONE® technology to offer a dedicated strategy for treating bifurcation lesions. Tryton's cobalt-chromium stent is deployed in the side branch artery using a standard, single-wire, balloon-expandable stent delivery system. A conventional drug eluting stent is then placed in the main vessel. The Tryton Side Branch Stent has now been used to treat more than 12,000 patients worldwide.

More information about the Tryton Side Branch stent will be available during TCT at the Cordis symposium, *Predictable Treatment of Complex Bifurcations using the TRYTON Side-Branch Stent*, on Monday, Oct. 30 from 1 – 2 p.m. at Presentation Theater 5 in the Colorado Convention Center, Denver.

## **About Cardinal Health**

Cardinal Health, Inc. is a global, integrated healthcare services and products company, providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories and physician offices worldwide. The company provides clinically proven medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency from hospital to home. Cardinal Health connects patients, providers, payers, pharmacists and manufacturers for integrated care coordination and better patient management. Because Cardinal Health helps ensure pharmacists and the consumers they serve have access to medications they need while working to help prevent prescription drug diversion, the company and its education partners created **Generation Rx**, a national program to help prevent the misuse of prescription medications. Backed by nearly 100 years of experience, with approximately 50,000 employees in nearly 60 countries, Cardinal Health ranks #15 on the *Fortune* 500. For more information, visit [cardinalhealth.com](http://cardinalhealth.com), follow

@CardinalHealth on Twitter and connect on LinkedIn at [linkedin.com/company/cardinal-health](https://www.linkedin.com/company/cardinal-health).

---

<http://cardinalhealth.mediaroom.com/newsreleasearchive?item=123137>